SAB Biotherapeutics (NASDAQ:SABS – Get Rating)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 419.48% from the company’s current price. SAB Biotherapeutics […]
HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Get Rating) in a research note published on Thursday morning, Benzinga reports. They currently have a $4.00 price target on the stock. SAB Biotherapeutics Stock Performance Shares of NASDAQ:SABS traded up $0.04 on Thursday, hitting $0.77. 962,873 shares of the company were […]
HC Wainwright reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Get Rating) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $4.00 price target on the stock. SAB Biotherapeutics Stock Down 6.7 % Shares of NASDAQ:SABS opened at $0.41 on Monday. The business’s 50-day moving average […]
HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Get Rating) in a research note released on Monday morning, Benzinga reports. The firm currently has a $4.00 target price on the stock. SAB Biotherapeutics Price Performance SAB Biotherapeutics stock opened at $0.44 on Monday. The stock’s 50 day moving average price […]
SAB Biotherapeutics (NASDAQ:SABS – Get Rating)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $4.00 target price on the stock. SAB Biotherapeutics Trading Up 4.1 % Shares of SABS stock opened at $0.48 on Monday. The […]